Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of subconjunctival bevacizumab injections on corneal neovascularization
2010-022858-16Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in corneal neovascularization (CNV) comparing Bevacizumab with Placebo (2 arms). Primary endpoint: Primary efficacy at 3 months. Started May 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on 2010-022858-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022858-16.